My Treatment Approach: Advancing Treatment Strategies for HER2+ Metastatic Breast Cancer - Episode 3
T-DXd and the DESTINY-Breast12 Trial for HER2+ Advanced BC With or Without Brain Mets
Panelists discuss the DESTINY-Breast12 trial, reviewing its study design, rationale, and key efficacy and safety findings in HER2-positive metastatic breast cancer patients with brain metastases, focusing on differences in outcomes between patients with active vs stable brain metastases, and the role of trastuzumab deruxtecan (T-DXd) in expanding treatment options for this patient population.
Video content above is prompted by the following:
- Briefly review the recent findings from the DESTINY-Breast12 trial, highlighting study design, rationale, and key efficacy and safety data in patients with HER2+ mBC and BM.
- How do the results differ between patients with and without baseline brain metastases, as well as those with active vs stable brain metastases?
- What role does trastuzumab deruxtecan (T-DXd) play in this treatment setting, and how do the trial findings expand its use in HER2-positive breast cancer with central nervous system involvement?
Related Content:
